Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBrainsway Ltd

Brainsway Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
10.335 USD -0.91 ( 8.05%)
Last update at 2026-11-12T15:42:00Z
VOLUME
65136
Market Cap
614.95M
P/E
85.17

Momentum Score

…

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.27
Low
10.95
High
52 Week Price Range
4.29
Low
16.27
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BrainsWay Ltd develops non-invasive neuromodulation systems based on proprietary deep transcranial magnetic stimulation for neuropsychiatric disorders. Long-term growth may be supported by broader clinical evidence, additional regulatory approvals and expanded reimbursement that could increase adoption, and investors may view the company as having differentiated IP and exposure to demand for non-drug treatment options.

Key risks include limited commercial scale and recurring losses, reliance on further regulatory clearances and reimbursement, competition from other neuromodulation and pharmacologic therapies, and variability in clinical outcomes.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.24
Dividend Yield
-
Revenue TTM
52.23M
Revenue Per Share
1.37
Gross Profit TTM
39.39M
Debt / Equity
0.09
ROE
11.26%
Net Debt
-61.13M
ROCE
4.80%
Diluted EPS TTM
0.18

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 7.77M 3.46M -3.95M -13.03M -6.42M
Net income 7.69M 2.92M -4.20M -13.35M -6.46M
Selling general administrative 25.46M 5.80M 15.72M 6.85M 5.78M
Selling and marketing expenses - 16.20M 5.92M 18.20M 15.88M
Gross profit 39.70M 30.58M 23.48M 20.05M 23.06M
Reconciled depreciation 1.54M 1.77M 1.34M 1.53M 1.69M
Ebit 4.36M 3.59M -3.90M -12.68M -5.00M
Ebitda 5.91M 5.36M -2.56M -11.15M -3.31M
Depreciation and amortization 1.55M 1.77M 1.34M 1.53M 1.69M
Operating income 4.36M 1.39M -4.96M -12.68M -5.00M
Other operating expenses 48.28M 39.62M 36.74M 39.86M 34.66M
Interest expense 2.23M 1.36M 0.30M 0.05M 1.42M
Tax provision 0.08M 0.54M 0.36M 0.32M 0.04M
Interest income 5.60M 2.48M 2.17M 1.11M 0.23M
Net interest income 3.39M 1.12M 1.88M -0.35M -1.42M
Income tax expense 0.08M 0.54M 0.25M 0.32M 0.04M
Total revenue 52.64M 41.02M 31.79M 27.18M 29.66M
Total operating expenses 35.34M 29.19M 28.44M 32.73M 28.06M
Cost of revenue 12.94M 10.44M 8.31M 7.13M 6.60M
Total other income expense net 3.41M 2.07M 1.01M -0.35M -1.42M
Net income from continuing ops 7.63M 2.92M -8.19M -13.35M -6.46M
Net income applicable to common shares - - - -13.35M -6.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 112.92M 94.32M 62.97M 64.48M 75.73M
Other current assets 5.69M 1.30M 1.71M 1.56M 1.77M
Total liab 34.67M 32.00M 15.31M 19.08M 18.41M
Total stockholder equity 73.22M 62.31M 41.58M 45.40M 57.32M
Other current liab 8.11M 5.66M 6.27M 5.31M 5.27M
Common stock 0.43M 0.41M 0.37M 0.36M 0.36M
Capital stock 0.43M 0.41M 0.37M 0.36M 0.36M
Retained earnings -90.75M -98.38M -101.30M -97.11M -83.76M
Other liab - - - 10.69M 9.34M
Other assets - 0.14M 0.00M 1.04M 0.95M
Cash 67.95M 69.34M 10.79M 47.58M 16.92M
Total current liabilities 22.16M 15.35M 9.76M 8.14M 9.07M
Current deferred revenue 10.55M 5.73M 2.50M 1.48M 2.19M
Net debt -61.13M -63.72M -10.32M -47.09M -16.17M
Short term debt 1.07M 0.82M 0.23M 0.23M 0.50M
Short long term debt total 6.82M 5.62M 0.47M 0.49M 0.75M
Other stockholder equity 162.22M 162.47M 140.34M 144.33M 142.91M
Property plant equipment - - - 5.35M 9.33M
Total current assets 84.89M 79.67M 55.47M 58.09M 65.45M
Long term investments 14.34M - - - -
Net tangible assets - - - 45.40M 57.32M
Short term investments 1.43M 0.00M 35.47M 0.27M 40.43M
Net receivables 4.11M 4.60M 3.78M 4.84M 6.33M
Inventory 7.13M 4.43M 3.72M 3.84M 0.20M
Accounts payable 2.43M 2.87M 0.76M 1.12M 1.10M
Accumulated other comprehensive income 1.32M -2.19M 2.17M -2.19M -2.19M
Non currrent assets other 1.52M 1.64M 0.89M 1.04M 0.95M
Non current assets total 28.03M 14.65M 7.51M 6.39M 10.29M
Capital lease obligations 6.82M 5.62M 0.47M 0.49M 0.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -15.77M 30.31M -1.53M 42.17M -40.00M
Change to liabilities - - - 0.79M 2.33M
Total cashflows from investing activities -17.63M 30.31M -37.41M 42.17M -42.22M
Net borrowings -0.83M -0.42M -0.27M -0.53M -0.47M
Total cash from financing activities -2.23M 18.26M -1.03M -1.55M 41.52M
Change to operating activities - - - -0.10M -0.41M
Net income 7.69M 2.92M -4.20M -13.35M -6.46M
Change in cash -1.67M 58.83M -37.06M 30.66M -0.04M
Begin period cash flow 69.62M 10.52M 47.58M 16.92M 16.96M
End period cash flow 67.95M 69.34M 10.52M 47.58M 16.92M
Total cash from operating activities 18.16M 10.30M 1.28M -9.76M 0.88M
Issuance of capital stock 0.00M 16.35M 0.00M - 42.26M
Depreciation 1.55M 1.77M 1.34M 1.53M 1.69M
Other cashflows from investing activities - 35.08M -35.02M -0.02M 0.02M
Change to inventory -2.00M -0.92M -0.51M -3.60M -0.41M
Change to account receivables 0.61M -0.87M 1.09M 1.46M -0.85M
Sale purchase of stock - 0.00M 0.00M -0.05M -
Other cashflows from financing activities -2.23M 2.33M -0.76M -0.96M -0.27M
Change to netincome - - - 3.51M 4.59M
Capital expenditures 1.76M 3.79M 2.39M 1.94M 2.24M
Change in working capital 7.65M 2.39M 1.64M -1.45M 1.07M
Stock based compensation 1.20M 1.42M 0.38M 1.47M 1.89M
Other non cash items 1.27M 1.80M 1.88M 1.72M 2.66M
Free cash flow 16.40M 6.50M -1.10M -7.82M -1.35M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BWAY
Brainsway Ltd		 -0.91
8.05%		 10.34 85.17 74.63 11.78 8.55 9.27 42.24
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.30
0.63%		 48.57 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Brainsway Ltd

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

16 Hartum St, Jerusalem, Israel, 9777516

972 2 582 4030

https://www.brainsway.com

120

Name Title Year Born
Dr. Christopher R. von Jako Ph.D. Pres & CEO 1969
Mr. Richard Scott Areglado Sr. VP & CFO 1964
Mr. Hadar Levy Sr. VP & COO 1974
Mr. Christopher J. Boyer Ph.D. VP of Global Marketing 1978
Mr. Avner Hagai Founder & Independent Vice-Chairman 1956
Prof. Abraham Zangen Co-Founder, Member of Scientific Advisory Board & Director 1970
Dr. Yiftach Roth Ph.D. Chief Scientist 1971
Mr. Menachem C. Klein Esq. VP, Gen. Counsel & Corp. Sec. NA
Dr. Aron Tendler Chief Medical Officer NA
Ms. Moria Ankri VP R&D 1984

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…